Polanco's Ankle Derails Met Hopes; $40M Contract Faces Season-Long Durability Risk

The New York Mets recalled Jorge Polanco from his Triple-A rehab assignment on Saturday for further testing on his left ankle after the veteran infielder reported soreness during his minor league work. Polanco was originally placed on the injured list on April 15 with a right wrist contusion and left Achilles bursitis—nearly two months ago from today's date—and was slated to test his health in Syracuse before a major league return. Instead, the Mets have opted to bring him back to New York for additional evaluation, a procedural reversal that signals lingering concern about the ankle's structural integrity.

The 32-year-old switch hitter has appeared in just 14 games since the Mets signed him to a two-year, $40 million contract this offseason to serve as Pete Alonso's replacement at the corner infield positions. His production has been sparse: a .179 batting average with one home run and two RBIs. More troubling than the early performance, however, is the pattern. Polanco's injury history has become a defining feature of his baseball profile. This is his seventh stint on the injured list since the 2022 season—roughly one IL trip every six months over a four-year span. That frequency is not random variance or bad luck. It reflects a body that has accumulated wear and may be entering a phase where soft-tissue injuries beget further soft-tissue injuries, a cascade problem that teams struggle to arrest mid-contract.

For the Mets, the financial implication is immediate. They committed $40 million to a player they expected to anchor the lineup for two seasons; instead, they have received 14 games of production at a .179 clip. The organization is now in a holding pattern—additional testing will determine whether Polanco can resume baseball activities or whether another extended shutdown is necessary. If the ankle requires weeks of rest or a change in his movement patterns, the window to trade Polanco or pivot the roster closes further into summer, when midseason acquisitions command higher prices and fewer quality arms remain available.

From a betting standpoint, Polanco's absence redistributes offensive responsibility in ways the market has not yet fully priced. The Mets' corner infield production was already thin; without Polanco and with Alonso now gone, the team is forced to piece together at bats from secondary batters and utility players. This matters for team total props and run-line wagering. The Mets' implied daily run production falls when they lose a $40 million bat—even one underperforming—because the substitute lineup lacks the same offensive ceiling. Over the next two weeks, before the market fully adjusts to a Polanco-absent lineup, team unders on the Mets may carry value, particularly in matchups against competent pitching. The broader angle is clear: if Polanco's ankle requires another month of recovery, the Mets' offensive profile dips measurably, and their pace-of-play dynamics shift toward fewer runs per game, not more.

The recurring injury pattern is also a lens for projecting future games. Polanco's durability is no longer an open question—it is a documented liability. Even if he returns and hits well in his next 10 games, the market will increasingly price in the risk of another IL stint before September. That psychological discount is already baked into his individual player props, but it hasn't yet fully cascaded into team total expectations. Fade Mets team overs in June while Polanco's status remains murky, and monitor the test results carefully; if he requires a second procedure or an extended shutdown, the durability angle becomes a persistent edge across the schedule.